🔗 Share this article America and Britain Announce Tariff-Free Arrangement on Prescription Drugs. Stock image of drug exports. The UK and US have finalized a major bilateral deal that will ensure no duties on British pharmaceutical shipments going into the American market. Agreement Details of the Deal As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key goods will stay at zero for a period of 36 months. This agreement is in response to recent warnings to significantly raise duties on branded drug imports, with figures discussed as high as double the cost. "This agreement with the UK strengthens the global environment for cutting-edge drugs and establishes much-needed balance to American-British drug exports," an announcement declared. Trade Importance Pharmaceuticals represent one of the UK's largest exports to the US, which is clearly the primary destination for large British pharmaceutical firms. Export figures reveal that in the 12 months prior to September, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount represented a significant portion of total UK exports in that period. "This guarantee protects jobs, increases investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," a government official commented. Specific UK Commitments The deal involves several key commitments from the British government: Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by twenty-five percent. Boosted Medicine Funding: There is a target to increase overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years. Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments were more than 20%. Recent Tensions This agreement takes place against a long-running tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption. The disagreement were heightened by claims that American customers were paying a premium for the same drugs than consumers in the UK and Europe. Over the last 18 months, several large manufacturing plans in the UK have been paused or cancelled, while substantial funding commitments have been pledged toward US facilities. One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.
Stock image of drug exports. The UK and US have finalized a major bilateral deal that will ensure no duties on British pharmaceutical shipments going into the American market. Agreement Details of the Deal As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key goods will stay at zero for a period of 36 months. This agreement is in response to recent warnings to significantly raise duties on branded drug imports, with figures discussed as high as double the cost. "This agreement with the UK strengthens the global environment for cutting-edge drugs and establishes much-needed balance to American-British drug exports," an announcement declared. Trade Importance Pharmaceuticals represent one of the UK's largest exports to the US, which is clearly the primary destination for large British pharmaceutical firms. Export figures reveal that in the 12 months prior to September, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount represented a significant portion of total UK exports in that period. "This guarantee protects jobs, increases investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," a government official commented. Specific UK Commitments The deal involves several key commitments from the British government: Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by twenty-five percent. Boosted Medicine Funding: There is a target to increase overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years. Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments were more than 20%. Recent Tensions This agreement takes place against a long-running tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption. The disagreement were heightened by claims that American customers were paying a premium for the same drugs than consumers in the UK and Europe. Over the last 18 months, several large manufacturing plans in the UK have been paused or cancelled, while substantial funding commitments have been pledged toward US facilities. One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.